Science News
from research organizations

Novel mode of antidepressant action may help patients unresponsive to SSRIs

Research has identified a serotonin type 3 receptor activator with antidepressant effects in mice that functions independently of SSRIs

Date:
April 25, 2017
Source:
Osaka University
Summary:
Scientists have identified a novel mode of action for a potential antidepressant that also leads to nerve cell growth in the mouse hippocampus. The activator of a serotonin receptor uses a different mechanism to the most commonly used antidepressants, SSRIs. This is a promising finding for the millions of patients who do not respond well to current treatments.
Share:
FULL STORY

Our histological analysis reveals that serotonin type 3 receptor (5HT3R) and insulin-like growth factor 1 (IGF1) are expressed in the same neurons in the subgranular zone of the hippocampal dentate gyrus. Furthermore, we show that 5HT3R agonist treatment increases hippocampal extracellular IGF1 levels, and that 5HT3R-dependent hippocampal neurogenesis is mediated by IGF1 signaling. In addition, we also show that 5HT3R agonist induces antidepressant effects as well as hippocampal neurogenesis independent of SSRIs. Altogether, our findings suggest a novel 5HT3R-IGF1 mechanism that is distinct from SSRI-induced responses and that provides a new therapeutic target for depression, especially bringing significant benefits for SSRI-resistant depressed patients.
Credit: Makoto Kondo

Antidepressants treat symptoms of depression by increasing levels of brain signaling molecules (neurotransmitters) such as serotonin, as with the most widely used type of antidepressant, selective serotonin reuptake inhibitors (SSRIs). However, many of the 350 million people worldwide thought to be affected with depression do not respond to SSRI treatment.

Now, researchers in the Department of Neuroscience and Cell Biology at Osaka University have found that an activator of the serotonin type 3 receptor (5HT3R) produces antidepressant effects in mice and increases nerve cell growth in the part of the brain responsible for memory and spatial navigation (the hippocampus). They also showed that it functions using a different mechanism than the commonly used SSRI fluoxetine, and therefore may be suitable for patients with depression who do not respond favorably to current medication.

The team of researchers used mice lacking part of 5HT3R to explore the function of the 5HT3R activator. The activator had antidepressant effects and initiated nerve cell growth in the hippocampus in control mice but not in those lacking part of the receptor.

In contrast, fluoxetine showed similar antidepressant actions and nerve cell growth in both control and knockout mice because it requires the type 1A rather than 5HT3R for its actions.

To explore the 5HT3R activator mode of action, hippocampal nerve cells expressing the receptor were chemically stained to investigate protein expression. The same cells were shown to express both the receptor and the growth factor IGF1.

"Treatment of control mice with the receptor activator led to increases in IGF1 secretion," study coauthor Shoichi Shimada says. "However, the activator had no effect in mice lacking part of the receptor." In addition, protein signaling involving IGF1 in the hippocampus was found to be necessary for nerve cell growth that was dependent on 5HT3R.

Fluoxetine must be given to patients for long periods to have any antidepressant effect, but just 3 days of 5HT3R activator treatment produced notable responses in mice.

"IGF1 combined with the activator produced characteristic changes in nerve cell growth that were not seen following fluoxetine administration," corresponding author Makoto Kondo says. "This may explain why the response times are so different."

Another difference is that the type 1A and 5HT3R are expressed in different cell types of the hippocampus which adds support to their use of distinct mechanisms of antidepressant action.


Story Source:

Materials provided by Osaka University. Note: Content may be edited for style and length.


Journal Reference:

  1. M Kondo, Y Koyama, Y Nakamura, S Shimada. A novel 5HT3 receptor–IGF1 mechanism distinct from SSRI-induced antidepressant effects. Molecular Psychiatry, 2017; DOI: 10.1038/mp.2017.87

Cite This Page:

Osaka University. "Novel mode of antidepressant action may help patients unresponsive to SSRIs: Research has identified a serotonin type 3 receptor activator with antidepressant effects in mice that functions independently of SSRIs." ScienceDaily. ScienceDaily, 25 April 2017. <www.sciencedaily.com/releases/2017/04/170425092331.htm>.
Osaka University. (2017, April 25). Novel mode of antidepressant action may help patients unresponsive to SSRIs: Research has identified a serotonin type 3 receptor activator with antidepressant effects in mice that functions independently of SSRIs. ScienceDaily. Retrieved May 25, 2017 from www.sciencedaily.com/releases/2017/04/170425092331.htm
Osaka University. "Novel mode of antidepressant action may help patients unresponsive to SSRIs: Research has identified a serotonin type 3 receptor activator with antidepressant effects in mice that functions independently of SSRIs." ScienceDaily. www.sciencedaily.com/releases/2017/04/170425092331.htm (accessed May 25, 2017).

RELATED STORIES